VYGR Earnings Prediction
The chart below shows how VYGR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VYGR sees a -4.25% change in stock price 10 days leading up to the earnings, and a -3.32% change 10 days following the report. On the earnings day itself, the stock moves by +4.13%. This data can give you a slight idea of what to expect for the next quarter's release.
VYGR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
24.63M
433.79%
-16.73%
Gross Margin
--
--
--
Operating Margin
-55.95%
-91.25%
35.37%
Net Margin
-36.72%
-93.46%
7.09%
EPS
-0.16
-72.88%
-11.11%
No Data Available
VYGR Earnings Analysis
Voyager Therapeutics, Inc. Common Stock Corporation (VYGR.O) Earnings Conference Call
Positive
Strong Cash Position: Voyager Therapeutics reported a strong cash position of $345 million at the end of Q3 2024, expected to provide runway into 2027.
Alzheimer's Drug Trial Progress: The company completed enrollment and dosing in the single ascending dose trial of VY7523, their anti-tau antibody for Alzheimer's disease.
Tau Targeting Approaches: Voyager is advancing two approaches to targeting tau, including their anti-tau antibody VY7523 and tau-silencing gene therapy, both of which are high priorities.
Clinical Development Update: The company expects to report topline safety and pharmacokinetic data in the first half of next year, indicating progress in their clinical development.
Strengthening Research Partnerships: Voyager's partnerships with leading experts in neurology and gene therapy continue to strengthen, enhancing their research capabilities.
Negative
Endpoint Not Achieved: The primary endpoint, CDR sum of boxes, was not met in the full study population.
Tau Accumulation Inhibition: The bepranemab inhibited the accumulation of tau in the human brain by 33% to 58%.
Cognitive Decline Reduction: The bepranemab demonstrated a cognitive decline by 21% to 25% versus placebo on ADAS-Cog14.
Tau Reduction in Trials: The bepranemab showed a reduction in pathological tau, as measured by PET imaging, but did not meet the primary endpoints in clinical trials.
Target Engagement Challenges: The study had insufficient target engagement with aggregated forms of amyloid beta, while the approved anti-amyloid antibodies all target the aggregated species.
VYGR FAQs
How does VYGR typically perform around its earnings report dates?
Is Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VYGR Earning Call Sentiment
Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VYGR.O
-2.91%Positive
The earnings call highlights strong financials with a $345 million cash position, robust pipeline development, and valuable partnerships with Novartis and Neurocrine. Despite regulatory and market risks, the company's strategic focus on gene therapy and tau-targeting therapies suggests potential long-term value creation. The Q&A section indicates positive sentiment towards the company's innovative approaches, although there are uncertainties in timing for certain milestones. Overall, the strategic initiatives and partnerships are likely to drive a positive stock price movement in the short term.
